Changing trends in the disease burden of non-melanoma skin cancer globally from 1990 to 2019 and its predicted level in 25 years.

Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

Original Publication: London : BioMed Central, [2001-

Global Burden of Disease* ; Skin Neoplasms*/epidemiology; Adult ; Bayes Theorem ; Cost of Illness ; Female ; Global Health ; Humans ; Incidence ; Male ; Quality-Adjusted Life Years ; Risk Factors

Background: The disease burden of non-melanoma skin cancer (NMSC) has become a significant public health threat. We aimed to conduct a comprehensive analysis to mitigate the health hazards of NMSC.
Methods: This study had three objectives. First, we reported the NMSC-related disease burden globally and for different subgroups (sex, socio-demographic index (SDI), etiology, and countries) in 2019. Second, we examined the temporal trend of the disease burden from 1990 to 2019. Finally, we used the Bayesian age-period-cohort (BAPC) model integrated nested Laplacian approximation to predict the disease burden in the coming 25 years. The Norpred age-period-cohort (APC) model and the Autoregressive Integrated Moving Average (ARIMA) model were used for sensitivity analysis.
Results: The disease burden was significantly higher in males than in females in 2019. The results showed significant differences in disease burden in different SDI regions. The better the socio-economic development, the heavier the disease burden of NMSC. The number of new cases and the ASIR of basal cell carcinoma (BCC) were higher than that of squamous cell carcinoma (SCC) in 2019 globally. However, the number of DALYs and the age-standardized DALYs rate were the opposite. There were statistically significant differences among different countries. The age-standardized incidence rate (ASIR) of NMSC increased from 54.08/100,000 (95% uncertainty interval (UI): 46.97, 62.08) in 1990 to 79.10/100,000 (95% UI: 72.29, 86.63) in 2019, with an estimated annual percentage change (EAPC) of 1.78. Other indicators (the number of new cases, the number of deaths, the number of disability-adjusted life years (DALYs), the age-standardized mortality rate (ASMR), and the age-standardized DALYs rate) showed the same trend. Our predictions suggested that the number of new cases, deaths, and DALYs attributable to NMSC would increase by at least 1.5 times from 2020 to 2044.
Conclusions: The disease burden attributable to NMSC will continue to increase or remain stable at high levels. Therefore, relevant policies should be developed to manage NMSC, and measures should be taken to target risk factors and high-risk groups.
(© 2022. The Author(s).)

JAMA Oncol. 2017 Dec 1;3(12):1683-1691. (PMID: 28983565)
Lancet. 2012 Dec 15;380(9859):2129-43. (PMID: 23245605)
Br J Dermatol. 2014 Sep;171(3):443-5. (PMID: 25234058)
J Dtsch Dermatol Ges. 2013 Apr;11(4):283-96; quiz 297-8. (PMID: 23574893)
Leukemia. 2005 Jun;19(6):984-9. (PMID: 15830009)
Lancet. 2020 Oct 17;396(10258):1285-1306. (PMID: 32679112)
Australas J Dermatol. 2019 Nov;60(4):265-272. (PMID: 30931531)
Adv Exp Med Biol. 2014;810:120-40. (PMID: 25207363)
Lancet. 2018 Nov 10;392(10159):1923-1994. (PMID: 30496105)
Stat Med. 2003 Sep 15;22(17):2751-66. (PMID: 12939784)
Future Oncol. 2015 Nov;11(22):2967-74. (PMID: 26466906)
Rev Port Cardiol (Engl Ed). 2020 Mar;39(3):163-170. (PMID: 32354458)
Biomark Res. 2020 May 13;8:16. (PMID: 32435498)
Nurs Stand. 2016 Nov 9;31(11):15. (PMID: 27848425)
Lancet. 2010 Feb 20;375(9715):673-85. (PMID: 20171403)
Brachytherapy. 2015 Nov-Dec;14(6):859-65. (PMID: 26489922)
Australas J Dermatol. 2015 Nov;56(4):258-67. (PMID: 25716064)
Arch Dermatol. 1999 Jul;135(7):781-6. (PMID: 10411152)
JAAD Int. 2020 Jul 28;1(2):95-103. (PMID: 34409328)
Lancet. 2019 Jan 19;393(10168):241-252. (PMID: 30554785)
Eur J Dermatol. 2019 Apr 1;29(2):185-191. (PMID: 31106760)
Soc Sci Med. 2008 Mar;66(5):1131-9. (PMID: 18164526)
Lancet. 2020 Oct 17;396(10258):1223-1249. (PMID: 33069327)
J Eur Acad Dermatol Venereol. 2004 Mar;18(2):142-7. (PMID: 15009290)
Geroscience. 2022 Apr;44(2):925-951. (PMID: 35000094)
Photodermatol Photoimmunol Photomed. 2019 Jan;35(1):24-30. (PMID: 30058127)
J Am Acad Dermatol. 2021 Aug;85(2):388-395. (PMID: 33852922)
CA Cancer J Clin. 2022 Jan;72(1):7-33. (PMID: 35020204)
Br J Dermatol. 2002 Jul;147(1):41-7. (PMID: 12100183)
Clin Oncol (R Coll Radiol). 2019 Nov;31(11):759-768. (PMID: 31522944)
Int J Clin Pract. 1998 Apr-May;52(3):145-9. (PMID: 9684427)
Cancer Treat Rev. 2001 Aug;27(4):201-9. (PMID: 11545540)
Dermatol Ther (Heidelb). 2017 Jan;7(Suppl 1):5-19. (PMID: 28150105)
Oral Oncol. 2020 Jan;100:104485. (PMID: 31821988)
Australas J Dermatol. 2018 Aug;59(3):210-213. (PMID: 29350397)
Oncol Lett. 2017 May;13(5):3787-3792. (PMID: 28521479)
Lancet. 2018 Nov 10;392(10159):1683. (PMID: 30415747)
Clin Med (Lond). 2016 Feb;16(1):62-5. (PMID: 26833519)
Semin Oncol Nurs. 2013 Aug;29(3):160-9. (PMID: 23958214)
Facial Plast Surg Clin North Am. 2012 Nov;20(4):419-22. (PMID: 23084294)
Adv Exp Med Biol. 2017;996:27-40. (PMID: 29124688)
Am J Epidemiol. 2013 Sep 15;178(6):890-7. (PMID: 23828250)
Endocrine. 2021 Aug;73(2):316-324. (PMID: 34101111)
Int J Cancer. 2019 Apr 15;144(8):1941-1953. (PMID: 30350310)
Endocrine. 2004 Nov;25(2):73-83. (PMID: 15711018)
Dermatoendocrinol. 2013 Jan 1;5(1):38-50. (PMID: 24494041)
Cancer Epidemiol. 2010 Dec;34(6):689-95. (PMID: 20638927)
Oral Oncol. 2019 Nov;98:96-101. (PMID: 31574416)
Occup Med (Lond). 2004 Oct;54(7):458-63. (PMID: 15486177)
Expert Opin Pharmacother. 2017 May;18(7):689-699. (PMID: 28414587)
Dermatol Ther. 2020 Nov;33(6):e14340. (PMID: 32975342)
Front Oncol. 2021 Dec 20;11:734354. (PMID: 34988009)
J Photochem Photobiol B. 2001 Oct;63(1-3):8-18. (PMID: 11684447)
Med J Aust. 2012 Nov 19;197(10):565-8. (PMID: 23163687)
Int J Cancer. 2001 Jan 20;95(1):7-11. (PMID: 11241303)
Aging Dis. 2017 Oct 1;8(5):643-661. (PMID: 28966807)
Adv Exp Med Biol. 2022;1367:397-409. (PMID: 35286705)
J Drugs Dermatol. 2017 May 1;16(5):464-469. (PMID: 28628682)
Curr Neurol Neurosci Rep. 2002 May;2(3):277-86. (PMID: 11937007)
J Am Coll Cardiol. 2020 Dec 22;76(25):2982-3021. (PMID: 33309175)

Keywords: Burden; Global; Non-melanoma skin cancer; Predict; Trend

Date Created: 20220730 Date Completed: 20220802 Latest Revision: 20220803

20221213

PMC9339183

10.1186/s12885-022-09940-3

35907848